Selumetinib with and without erlotinib in KRAS mutant and KRAS wild-type advanced nonsmall-cell lung cancer

Annals of Oncology : Official Journal of the European Society for Medical Oncology
C A CarterG Giaccone

Abstract

KRAS mutations in NSCLC are associated with a lack of response to epidermal growth factor receptor inhibitors. Selumetinib (AZD6244; ARRY-142886) is an oral selective MEK kinase inhibitor of the Ras/Raf/MEK/ERK pathway. Advanced nonsmall-cell lung cancer (NSCLC) patients failing one to two prior regimens underwent KRAS profiling. KRAS wild-type patients were randomized to erlotinib (150 mg daily) or a combination of selumetinib (150 mg daily) with erlotinib (100 mg daily). KRAS mutant patients were randomized to selumetinib (75 mg b.i.d.) or the combination. The primary end points were progression-free survival (PFS) for the KRAS wild-type cohort and objective response rate (ORR) for the KRAS mutant cohort. Biomarker studies of ERK phosphorylation and immune subsets were carried out. From March 2010 to May 2013, 89 patients were screened; 41 KRAS mutant and 38 KRAS wild-type patients were enrolled. Median PFS in the KRAS wild-type arm was 2.4 months [95% confidence interval (CI) 1.3-3.7] for erlotinib alone and 2.1 months (95% CI 1.8-5.1) for the combination. The ORR in the KRAS mutant group was 0% (95% CI 0.0% to 33.6%) for selumetinib alone and 10% (95% CI 2.1% to 26.3%) for the combination. Combination therapy resulted in in...Continue Reading

References

Oct 7, 1995·BMJ : British Medical Journal·D P Carbone, J D Minna
Jun 23, 1995·The Journal of Biological Chemistry·M H Cobb, E J Goldsmith
Jul 15, 2005·The New England Journal of Medicine·Frances A ShepherdUNKNOWN National Cancer Institute of Canada Clinical Trials Group
Nov 8, 2005·Nature·David B SolitNeal Rosen
Mar 3, 2007·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Tammie C YehEli Wallace
May 17, 2007·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Erminia MassarelliIgnacio I Wistuba
Oct 25, 2008·Nature·Li DingRichard K Wilson
Dec 23, 2008·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·E A EisenhauerJ Verweij
Feb 2, 2010·Nature Reviews. Clinical Oncology·Joel W Neal, Lecia V Sequist
Feb 25, 2010·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Udai BanerjiCarla M L van Herpen
Aug 31, 2010·Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer·John D HainsworthValentina Tzekova
Feb 4, 2012·Nature Reviews. Drug Discovery·Lorenzo GalluzziGuido Kroemer
Feb 14, 2012·Nature Medicine·Kengo TakeuchiYuichi Ishikawa
Nov 20, 2012·Annual Review of Immunology·Guido KroemerLaurence Zitvogel
Apr 24, 2013·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Julien MazièresOliver Gautschi
Jan 9, 2014·CA: a Cancer Journal for Clinicians·Rebecca SiegelAhmedin Jemal
Oct 9, 2014·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Trevor E AngellAlan L Epstein
Feb 11, 2015·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Ariel Lopez-ChavezGiuseppe Giaccone

❮ Previous
Next ❯

Citations

Jul 29, 2016·Future Oncology·Reyes BernabéEmma Dean
Jul 19, 2016·Expert Opinion on Biological Therapy·Jiali YangWilliam C Cho
Nov 30, 2016·Nature Communications·Erdem BangiRoss L Cagan
Jul 5, 2017·Expert Opinion on Investigational Drugs·Francesca CasaluceCesare Gridelli
Jan 11, 2019·International Journal of Cancer. Journal International Du Cancer·Ying ChengHongqi Tian
Apr 12, 2019·The Journal of Pathology·Thijs S StutvoetSteven de Jong
Oct 28, 2019·Cancers·Cornelia BraicuIoana Berindan-Neagoe
Sep 3, 2019·Current Topics in Medicinal Chemistry·Hao HeLei Zheng
Sep 3, 2019·Current Topics in Medicinal Chemistry·Fengqian ChenQi Liu
Feb 22, 2018·Oncotarget·Marzia Del ReRomano Danesi
Jun 23, 2020·FASEB Journal : Official Publication of the Federation of American Societies for Experimental Biology·Christian F RuizJohn D Haley
Apr 27, 2017·Frontiers in Medicine·Raghav SundarTimothy A Yap
Dec 9, 2017·Expert Opinion on Investigational Drugs·Chul Kim, Giuseppe Giaccone
Jun 18, 2020·Cancer Metastasis Reviews·Aron GhimessyZsolt Megyesfalvi
Jun 13, 2020·Nature Reviews. Drug Discovery·Amanda R MooreShiva Malek
Jan 15, 2019·Cancer Cell International·Marta Llaurado FernandezMark S Carey
Dec 22, 2016·CNS Oncology·Souvik Karmakar, Karlyne M Reilly
Jun 21, 2020·International Journal of Molecular Sciences·Iris Z UrasEmilio Casanova
Oct 27, 2020·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Timothy F BurnsSolange Peters
Oct 22, 2017·Cancer Discovery·Maria RusanPeter S Hammerman
Nov 25, 2020·European Journal of Medicinal Chemistry·Claudia Korzeniecki, Ronny Priefer
Feb 17, 2021·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Nasser H HannaGregory Masters
Jan 7, 2021·Journal of Hematology & Oncology·Jing HanQiming Wang
Mar 30, 2021·Frontiers in Cell and Developmental Biology·Alessandro TubitaElisabetta Rovida
Dec 18, 2021·Molecular Biomedicine·Kulshrestha Ritu Rajkumar

❮ Previous
Next ❯

Related Concepts

Related Feeds

Cell Checkpoints & Regulators

Cell cycle checkpoints are a series of complex checkpoint mechanisms that detect DNA abnormalities and ensure that DNA replication and repair are complete before cell division. They are primarily regulated by cyclins, cyclin-dependent kinases, and the anaphase-promoting complex/cyclosome. Here is the latest research.

Anthelmintics

Anthelmintics or antihelminthics are a group of antiparasitic drugs that expel parasitic worms (helminths) and other internal parasites from the body by either stunning or killing them and without causing significant damage to the host. Discover the latest research on anthelmintics here.

Apoptosis

Apoptosis is a specific process that leads to programmed cell death through the activation of an evolutionary conserved intracellular pathway leading to pathognomic cellular changes distinct from cellular necrosis

Related Papers

Lung Cancer : Journal of the International Association for the Study of Lung Cancer
Qiong ZhangJun-Qing Han
Lung Cancer : Journal of the International Association for the Study of Lung Cancer
Thomas E Stinchcombe, Gary L Johnson
© 2022 Meta ULC. All rights reserved